Health Capsule

Pancreatic cancer is considered one of the most lethal forms of cancer. A major reason for its high death rate is that it is often discovered only after it has already spread to other areas of the body. Once the disease has advanced, available treatments are far less effective.

At present, there are no routine screening tools that reliably detect pancreatic cancer in its earliest stages. However, a recent study explored new methods aimed at identifying the disease sooner.

Scientists analyzed blood samples from 672 individuals. The group included both patients diagnosed with pancreatic cancer and individuals without the disease. Researchers also examined samples from people with other pancreatic disorders, such as pancreatitis.

The investigators discovered that patients with early-stage pancreatic cancer showed elevated levels of two specific proteins in their blood. The newly developed test measures these two proteins. In addition, it screens for two other proteins that may signal pancreatic cancer in certain patients.

When used together, these markers helped differentiate cancer patients from those without cancer. The test accurately detected pancreatic cancer in approximately 92% of cases. It also identified early-stage cancers in about 87% of patients.

“Pancreatic cancer typically does not cause noticeable symptoms until surgery is no longer an option,” explains Dr. Kenneth Zaret of the University of Pennsylvania. Detecting the disease at an earlier point could improve a patient’s opportunity to receive effective treatment and increase survival rates.

Further studies involving larger populations are necessary to validate these findings and determine how well the test performs in broader clinical settings.